SCHEDULE 13G/A: BlackRock Maintains 15% Stake in Arrowhead Pharma
Beneficial Ownership Report (Schedule 13G)
BlackRock, Inc. has reported a 15.0% beneficial ownership stake in Arrowhead Pharmaceuticals Inc., holding over 20 million shares as of December 31, 2025.
Summary
- BlackRock, Inc. filed an Amendment No. 4 to Schedule 13G, reporting its beneficial ownership in Arrowhead Pharmaceuticals Inc.
- As of December 31, 2025, BlackRock beneficially owned 20,323,221 shares of Arrowhead Pharmaceuticals Inc. Common Stock.
- This ownership represents 15.0% of the total class of securities outstanding.
- BlackRock holds sole voting power over 20,124,285 shares and sole dispositive power over 20,323,221 shares.
- The securities were acquired and are held in the ordinary course of business, not for the purpose of changing or influencing control of the issuer.
- iShares Core S&P Small-Cap ETF, a BlackRock entity, holds more than 5% of the total outstanding common stock of Arrowhead Pharmaceuticals Inc.
Sentiment
Score: 7
Explanation: A large, maintained institutional holding by BlackRock suggests continued confidence in the issuer's long-term prospects, although the filing itself is purely an ownership disclosure.
Positives
- BlackRock, a major institutional investor, maintains a significant 15.0% stake in Arrowhead Pharmaceuticals Inc., indicating continued institutional confidence or strategic inclusion in their investment vehicles.
Industry Context
BlackRock is one of the world's largest asset managers. Its significant and maintained stake in Arrowhead Pharmaceuticals suggests that the company is either a core holding within BlackRock's managed funds (such as the iShares Core S&P Small-Cap ETF mentioned) or represents a strategic investment, which can be viewed positively by the market.
Stakeholder Impact
- Shareholders: BlackRock's continued significant holding may instill confidence among existing shareholders and potentially attract new investors, given BlackRock's reputation as a major institutional investor.
Key Dates
| Date | Description |
|---|---|
| April 30, 2023 | Date of previous Power of Attorney that was revoked. |
| January 21, 2025 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| December 31, 2025 | Date of the event which requires the filing of this statement (reporting period end). |
| January 21, 2026 | Signature date of the Schedule 13G filing by BlackRock, Inc. |
Recommendation
holdBlackRock's significant and maintained 15% stake in Arrowhead Pharmaceuticals indicates continued institutional confidence. However, this filing is purely an ownership disclosure and does not provide new financial performance data, operational updates, or strategic insights necessary for a more definitive investment recommendation. Therefore, a 'hold' recommendation is appropriate, acknowledging the positive signal of institutional backing without new fundamental information.
Keywords
Arrowhead Pharmaceuticals, BlackRock, Institutional Ownership, Schedule 13G, Beneficial Ownership, Common Stock, Investment Management, Biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.